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The REJOICE trial: a phase 3 randomized, controlled trial evaluating
the safety and efficacy of a novel vaginal estradiol soft-gel capsule for
symptomatic vulvar and vaginal atrophy
Ginger D. Constantine, MD,1 James A. Simon, MD,2 James H. Pickar, MD,3 David F. Archer, MD,4
Harvey Kushner, PhD,5 Brian Bernick, MD,6 Gina Gasper, BA,6 Shelli Graham, PhD,6 and
Sebastian Mirkin, MD,6 on behalf of the REJOICE Study Group
Abstract
Objective: To evaluate the safety and efficacy of TX-004HR vaginal estradiol soft-gel capsules for moderate-tosevere dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
Methods: In this randomized, double-blind, placebo-controlled, phase 3 study, postmenopausal women with a selfidentified most bothersome symptom of dyspareunia received 4, 10, or 25 mg TX-004HR or placebo for 12 weeks. Four
co-primary efficacy endpoints were change from baseline to week 12 in percentages of superficial and parabasal cells,
vaginal pH, and severity of dyspareunia. Secondary endpoints included severity of vaginal dryness and vulvar and/or
vaginal itching or irritation. Endometrial histology and adverse events (AEs) were included in the safety endpoints.
Results: In all, 764 women were randomized (modified intent-to-treat population, n ¼ 747; mean age 59 y).
Compared with placebo, all three doses of TX-004HR significantly improved the four co-primary endpoints
(P < 0.0001 for all, except dyspareunia with 4 mg, P ¼ 0.0149). Changes in cytology, pH, and dyspareunia were also
significant at weeks 2, 6, and 8. Vaginal dryness and vaginal itching/irritation improved. Sex hormone binding
globulin concentrations did not change with treatment. TX-004HR was well-tolerated, with no clinically meaningful
differences in treatment-emergent AEs versus placebo, and no treatment-related serious AEs or deaths.
Conclusions: TX-004HR (4, 10, and 25 mg) was safe, well-tolerated, and effective for treating moderate-tosevere dyspareunia within 2 weeks with minimal systemic estrogen exposure. This novel product may be a potential
new treatment option for women experiencing postmenopausal vulvar and vaginal atrophy.
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ostmenopausal vulvar and vaginal atrophy (VVA) is
the thinning, drying, and loss of elasticity of the
vaginal epithelium associated with the reduction in
serum estrogen after menopause.1 Up to approximately 70%
of postmenopausal women show clinical evidence of VVA,2
and roughly half report symptoms associated with VVA,
including vaginal dryness, irritation, itching, dysuria, and
pain or bleeding with sexual activity.3,4 These clinical signs
and symptoms of VVA are a component of the more encompassing term of genitourinary syndrome of menopause
(GSM).5 VVA is progressive without treatment,6 and can
negatively affect quality of life.7 A recent survey of 3,046
postmenopausal women with symptoms of VVA reported that
only 7% of the women currently used prescription-only
therapy to treat their VVA,8 and in the United States,
32 million postmenopausal women are thought to have
symptomatic VVA.8,9 Thus, it is believed that the majority
of postmenopausal women with symptomatic VVA are not
being treated.
Low-dose vaginal estrogens are recognized as safe and
effective treatment options for women with moderate-tosevere symptoms of VVA.10,11 Local low-dose vaginal estrogens result in lower levels of circulating estrogen than oral or
transdermal therapies. The Working Group on Women’s
Health and Well-Being in Menopause, whose participants
have affiliations with a number of medical societies and
professional organizations, has proposed to the US Food
and Drug Administration (FDA) the removal of the bold-font
boxed warning from the product label of vaginal estrogens to
help facilitate the prescription of these products, since the
current boxed warning may be only relevant to higher doses of
systemic estrogen, but not low-dose vaginal estrogens.12
Despite the positive risk-benefit profile of vaginal estrogen
treatments, many women are dissatisfied with currently available products.8 Creams require a reusable applicator (which
may be unsanitary) and can be messy, inconvenient, and
difficult to properly administer.13,14 Currently available vaginal tablets also have the inconveniences of an applicator
which may be difficult to use and may cause vaginal
abrasions.15 Vaginal discharge lasting for days and perceived
lack of efficacy have also been associated with vaginal
tablets.16 An analysis of prescription renewals in the United
States showed that most women discontinue use of vaginal
creams and vaginal tablets after an average use of only 45 and
103 days, respectively.17 Vaginal rings are not widely used,
but can require dexterity for insertion and can dislodge,1,10
and many women do not favor a long-term vaginal device.
Women also have concerns regarding long-term safety and
the risks of systemic absorption related to some of the
available vaginal products.16 Further, many women prefer
to use estrogen identical to their endogenous estrogen (ie,
17b-estradiol) as opposed to conjugated equine estrogens,
which are contained in some vaginal products.18
TX-004HR (TherapeuticsMD, Inc, Boca Raton, FL) is a
vaginal 17b-estradiol product in development, designed to
rapidly and effectively treat symptoms of VVA without
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increasing serum estradiol levels, and to provide easy insertion with complete and rapid dissolution to minimize vaginal
discharge. The muco-adhesive soft-gel capsule (VagiCap)
contains solubilized estradiol and is administered without
an applicator for ease of use and improved user experience.
Estradiol is released after dissolution of the soft-gel capsule
within the vagina, and does not require vaginal secretions to
activate the process.
Phase 1 studies have shown that women have two to three
times lower systemic estrogen concentrations 24 hours after
vaginal insertion of 10 and 25 mg TX-004HR than with a
regulatory approved and commercially available low-dose
vaginal estradiol tablet at identical doses.19 The primary
objective of this study was to evaluate the safety and efficacy
of three doses of the investigational drug, TX-004HR (4, 10,
and 25 mg), compared with placebo, in postmenopausal
women at 12 weeks for the treatment of moderate-to-severe
dyspareunia and VVA, components of GSM. Efficacy
outcomes included changes from baseline in vaginal superficial and parabasal cells, vaginal pH, and the severity of
dyspareunia associated with VVA as the most bothersome
symptom (MBS).
METHODS
Study design
This 12-week, multicenter, double-blind, randomized,
placebo-controlled, phase 3 trial was conducted at 89 sites
in the United States and Canada (NCT02253173) from October 2014 to October 2015. Eligible women were randomized
(1:1:1:1) to either TX-004HR 4, 10, or 25 mg, or matching
placebo in soft-gel capsules specifically designed for vaginal
insertion. Randomization was achieved using a computergenerated randomization schedule prepared by a statistician
before the start of the study. Women were instructed to
digitally self-administer one soft-gel capsule into the vagina
at approximately the same time of day, daily for 2 weeks, and
then twice weekly (approximately 3-4 d apart) for 10 weeks.
All study staff, sponsor representatives, and study participants
were blinded throughout the study until database lock, with
the blind to be broken only to protect participant safety in
emergency situations.
The study was conducted in accordance with applicable
laws and regulations, including, but not limited to, the International Conference on Harmonization Guideline for Good
Clinical Practice and the ethical principles that have their
origins in the Declaration of Helsinki. The study protocol and
the informed consent form were approved by an independent
institutional review board (IRB).
Study participants
Participants signed written informed consent before
any study-related activities. Postmenopausal women 40 to
75 years of age were enrolled if they had 5% superficial
cells on vaginal cytological smear; vaginal pH > 5.0; MBS
of moderate-to-severe vaginal pain associated with
sexual activity (dyspareunia); onset of moderate-to-severe
ß 2016 The Author(s)
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dyspareunia after menopause; body mass index 38 kg/m2;
and were sexually active (with vaginal penetration) and
anticipated having sexual activity during the trial period.
Participants with an intact uterus must have had a screening
endometrial biopsy sample sufficient for analysis.
Women were excluded from the study if they had a history
or active presence of clinically important medical disease that
might confound the study or be detrimental to their health.
Key exclusion criteria included endometrial hyperplasia or
cancer; undiagnosed vaginal bleeding; liver or kidney disorder; thromboembolic disorders; cerebrovascular accident,
stroke, or transient ischemic attack; myocardial infarction or
ischemic heart disease; malignancy; or endocrine disease; or
any clinically important abnormalities on screening physical
examination, assessments, mammogram, electrocardiogram
(ECG), or laboratory tests. Women with a recent history of
alcohol or drug abuse, or a history of sexual or spousal abuse
were excluded, as were current heavy smokers or users of ecigarettes or marijuana.
Women could not have used oral products containing
estrogens, progestins, androgens, or selective estrogen
receptor modulators (SERMs) within 8 weeks; transdermal
hormone products within 4 weeks; vaginal hormone products
(rings, creams, gels) within 4 weeks; intrauterine progestins
within 8 weeks; progestin implants/injectables or estrogen
pellets/injectables within 6 months; vaginal lubricants or
moisturizers within 7 days before vaginal pH assessment
during screening; investigational drugs within 60 days; or
an intrauterine device within 12 weeks before screening.
Concomitant medications were allowed during the study
(and were to be recorded in diaries), with the exception of
investigational drugs; estrogen, progestin, androgen, or
SERM-containing medications other than TX-004HR, and
also prescription and nonprescription medications/remedies
known to treat VVA, including vaginal lubricants and
moisturizers.
Efficacy parameters
The four co-primary efficacy endpoints analyzed for each
dose were change from baseline to week 12 compared with
placebo in (1) percentage of vaginal superficial cells, (2)
percentage of vaginal parabasal cells, (3) vaginal pH, and (4)
severity of the MBS of dyspareunia associated with VVA.
Secondary efficacy endpoints included change from baseline
to weeks 2, 6, and 8 compared with placebo for the four above
endpoints. Additional secondary endpoints were change from
baseline to weeks 2, 6, 8, and 12 in the severity of vaginal
dryness and vulvar and/or vaginal itching or irritation associated with VVA.
Vaginal cytology was assessed by a vaginal smear, and
vaginal pH was measured by comparing an indicator strip
applied to the lateral vaginal wall with a colorimetric scale at
screening, and at weeks 2, 6, 8, and 12. Participants were
asked to identify their MBS and self-assess their symptoms of
VVA including vaginal pain associated with sexual activity,
vaginal dryness, and vulvar and/or vaginal itching or irritation

using the VVA Symptom Self-Assessment Questionnaire
(scoring: 0 ¼ none, 1 ¼ mild, 2 ¼ moderate, 3 ¼ severe) at
screening. Women were re-assessed by this questionnaire
at weeks 2, 6, 8, and 12.
Safety
Safety endpoints included vital signs, clinical laboratory
tests (blood chemistry, hematology, hormone levels, urine
analysis), ECG, physical and gynecological examination
findings, pap smears, endometrial biopsies, and adverse
events (AEs). AEs included undesirable medical conditions
occurring at any time during all study phases including the
washout period, whether or not a study treatment had been
administered. An AE was considered treatment-emergent if it
occurred after study drug administration, or if it was preexisting and worsened during 120 days postdose follow-up.
Participants were given a diary with instructions to record
product use, sexual activity, symptoms/complaints, and other
medications. AEs, concomitant medications, and vital signs
were recorded and assessed at each study visit from screening
to week 12.
Endometrial biopsies were collected at baseline and at
week 12, or end of treatment. A diagnosis of endometrial
hyperplasia from the biopsy was based on agreement of two of
three reads by independent pathologists blinded to treatment.
Statistical analyses
A sample size of 140 participants per treatment arm was
calculated using data from the product literature to achieve
50% to >99% power to detect a 30% to 71% change in the
severity of dyspareunia (0.005 one-tailed significance level)
in the modified intent-to-treat (MITT) population.
The intent-to-treat (ITT) and safety populations were the
same and included all women who were randomized and
received at least one dose of TX-004HR. Those in the ITT
population with baseline values for each co-primary endpoint
and at least one follow-up value for any of the co-primary
endpoints formed the MITT population, which was the
primary efficacy population.
Statistical analyses were performed using SAS Release 9.2.
Baseline and demographic variables were descriptively summarized by treatment group. A stepwise procedure was used
to account for the multiple doses and endpoints. Primary and
secondary endpoints were compared with placebo using
analyses of covariance (ANCOVAs) based on mixed-effects
model repeated measures (MMRM) methods with participant
as the random effect and treatment group and visit (2, 6, 8, and
12 wks) as the fixed effects, with an interaction term for visit
and treatment. Baseline measures and age were covariates.
Pair-wise comparisons were performed using ANCOVA for
each dose of TX-004HR versus placebo. Data comparisons
were considered statistically significant at an alpha level of
0.05. No last observation carried forward methods for efficacy
were used for missing or invalid (when multiple laboratory
data provided contradictory or ambiguous results) data, as per
MMRM methods.
Menopause, Vol. 24, No. 4, 2017
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The number and proportion of women reporting each AE
and serious AE in each treatment group were summarized.
An AE was counted once for a participant if they had the same
AE more than once. Actual values and change from baseline
in blood chemistry parameters were summarized for each
treatment group.
RESULTS
Participant disposition and baseline characteristics
Of 2,183 women screened, 764 were eligible and randomized to TX-004HR 4 mg (n ¼ 191), 10 mg (n ¼ 191), 25 mg
(n ¼ 190), or placebo (n ¼ 192; Fig. 1), and were included in
the safety population. Ninety-two percent (704/764) of the
participants completed the study, and 94% (703/747) of
women in the MITT population completed the study (Fig. 1).
Demographic and baseline characteristics of the MITT
population were similar among groups (Table 1). Women
had a mean age of 59 years, ranging from 40 to 75 years, and a
mean BMI of 27 kg/m2; the majority were white. No significant differences between each treatment group versus placebo
were found in baseline superficial cells, parabasal cells,
vaginal pH, and severity score for dyspareunia (Table 1).
In the MITT population, the mean severity score for vaginal
dryness was 2.4 at baseline, with approximately 93% of
women having moderate-to-severe vaginal dryness. The mean
severity score for vulvar and/or vaginal itching or irritation
was 1.2, with approximately 42% of women having moderateto-severe itching or irritation. No significant differences
between each treatment group versus placebo were found
in these baseline parameters.

Vaginal cytology, vaginal pH, and dyspareunia
(co-primary endpoints)
Compared with placebo, 4, 10, and 25 mg TX-004HR
significantly improved the four co-primary endpoints from
baseline to week 12 in the percentage of superficial cells, the
percentage of parabasal cells, vaginal pH, and the severity
score for dyspareunia (P < 0.0001 for all, except P ¼ 0.0149
for dyspareunia with 4 mg; Table 2; Fig. 2A-D). The increase
in the percentage of superficial cells ranged from 17% to 23%
for TX-004HR doses, compared with 6% for placebo, whereas
the decrease in parabasal cells ranged from 41% to 46% for
TX-004HR doses versus 7% for placebo from baseline to
week 12. The percentages of superficial and parabasal cells
and vaginal pH also all significantly improved from baseline
to weeks 2, 6, and 8 for all three doses of TX-004HR
compared with placebo (P < 0.0001 for all; Table 2).
At week 12, mean dyspareunia severity scores for women
assigned to TX-004HR were 1.1, 0.9, and 1.0 for 4, 10, and
25 mg, respectively, whereas the mean score for women
assigned to placebo was 1.4. The MBS of dyspareunia also
significantly improved for women taking TX-004HR at all
doses compared with placebo at weeks 2, 6, and 8 (Table 2).
Vaginal dryness and vulvar and/or vaginal itching or
irritation
Vaginal dryness significantly improved with all three doses
of TX-004HR at week 12 from baseline compared with
placebo (P < 0.01 for 4 mg, P < 0.0001 for 10 mg and
25 mg; Fig. 3A) in the MITT population. Statistically significant differences in vaginal dryness scores were noted between

Participants screened for eligibility
(n = 2,183)

Screen failures
(n = 1,419)

Randomized to treatment
(n = 764)

TX-004HR 4 µg
Safety population (n = 191)
MITT population (n = 186)

TX-004HR 10 µg
Safety population (n = 191)
MITT population (n = 188)

TX-004HR 25 µg
Safety population (n = 190)
MITT population (n = 186)

Placebo
Safety population (n = 192)
MITT population (n = 187)

MITT Completed (n = 175)
Discontinued (n = 11)
Adverse event (n = 1)
Lack of efficacy (n = 2)
Lost to follow up (n = 2)
Protocol violation (n = 1)
Withdrew consent (n = 5)

MITT Completed (n = 174)
Discontinued (n = 14)
Adverse event (n = 3)
Investigator decision (n = 1)
Lack of efficacy (n = 2)
Lost to follow up (n = 3)
Protocol violation (n = 1)
Withdrew consent (n = 4)

MITT Completed (n = 177)
Discontinued (n = 9)
Adverse event (n = 2)
Investigator decision (n = 1)
Lost to follow up (n = 1)
Withdrew consent (n = 5)

MITT Completed (n = 177)
Discontinued (n = 10)
Adverse event (n = 3)
Lost to follow up (n = 3)
Withdrew consent (n = 4)

FIG. 1. Participant disposition through the study. MITT, modified intent-to-treat.
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TABLE 1. Participant demographics and baseline characteristics (MITT population)
Characteristic

TX-004HR 4 mg (n ¼ 186)

TX-004HR 10 mg (n ¼ 188)

TX-004HR 25 mg (n ¼ 186)

Placebo (n ¼ 187)

59.8 (6.0)

58.6 (6.3)

58.8 (6.2)

59.4 (6.0)

162
20
3
26.6
87
1.3
52.3
6.3
2.7

165
21
2
26.8
86
1.2
51.3
6.3
2.6

161
24
1
26.8
85
1.3
53.5
6.3
2.7

160
21
1
26.6
73
1.3
52.0
6.3
2.7

Age, mean (SD), y
Race, n (%)
White
Black or African American
Asian
BMI, mean (SD), kg/m2
Hysterectomized, n (%)
Superficial cells, mean (SD), %
Parabasal cells, mean (SD), %
Vaginal pH, mean (SD)
Dyspareunia, severity score, mean (SD)

(87.1)
(10.8)
(1.6)
(4.9)
(46.8)
(1.2)
(39.2)
(0.9)
(0.5)

(87.8)
(11.2)
(1.1)
(4.7)
(45.7)
(1.2)
(38.0)
(0.8)
(0.5)

(86.6)
(12.9)
(0.5)
(4.8)
(45.7)
(1.2)
(38.3)
(0.9)
(0.4)

(85.6)
(11.2)
(0.5)
(4.6)
(39.0)
(1.3)
(39.2)
(1.0)
(0.5)

BMI, body mass index; MITT, modified intent-to-treat.

TX-004HR 10 and 25 mg versus placebo at week 2 (P < 0.01
for both), and with all doses of TX-004HR versus placebo at
week 6 (P < 0.01 for 4 mg, P < 0.001 for 10 mg and 25 mg) and
week 8 (P < 0.05 for 4 mg, P < 0.0001 for 10 mg, and
P < 0.001 for 25 mg).
The mean severity score for vulvar and/or vaginal itching or
irritation decreased to 0.4 at week 12 for women in both 10
and 25-mg groups, which was significantly greater than the
change observed from baseline with placebo (P ¼ 0.0055 and
P ¼ 0.0263, respectively; Fig. 3B). The mean severity score at
week 12 was 0.5 (P ¼ 0.0503 vs placebo) in the 4-mg group.

numerically fewer women in any of the TX-004HR groups
than by women in the placebo group. Most TEAEs were mild
to moderate in severity. Few participants (1.8%) discontinued
the study due to AEs.
Nine serious TEAEs were reported in eight women; however, none was considered related to treatment. Complete
heart block, appendicitis, endophthalmitis, and chronic
obstructive pulmonary disease were each reported by a different participant in the 25-mg group. Sinus node dysfunction
and ankle fracture were both reported for one women, and
arthralgia and malignant melanoma were each reported for
one women in the 10-mg group. None of the women in the
4-mg group had reports of serious TEAEs. One woman in the
placebo group was reported to have a cervical myelopathy. No
deaths occurred during the study.
No diagnoses of endometrial hyperplasia or malignancy
from endometrial biopsies were observed at week 12. Total
cholesterol numerically decreased from baseline to week 12
by a mean of 0.024 to 0.07 mmol/L in the treatment groups,
and by 0.008 mmol/L in the placebo group. No clinically
meaningful increases in triglycerides were observed in any
active treatment groups compared with placebo. Sex hormone

Safety
TX-004HR had a favorable safety profile and was welltolerated. No clinically significant differences in AEs were
observed between treatment and placebo groups (Table 3).
Headache was the most commonly reported TEAE, followed
by vaginal discharge, nasopharyngitis, and vulvovaginal pruritus (Table 3). Headache was the only treatment-related
TEAE that was numerically more frequent in women receiving TX-004HR than those receiving placebo (3.7% for 4-mg
dose vs 3.1% for placebo). Vaginal discharge was reported by

TABLE 2. Change from baseline (LS means  SE) at weeks 2, 6, 8, and 12 for the 4 co-primary endpoints (MITT population)
% Superficial cells
TX-004HR
4 mg

10 mg

25 mg

Placebo

% Parabasal cells
a

Vaginal pH
a

Dyspareunia (score)
a

Week

n

LS mean  SE

P

n

LS mean  SE

P

n

LS mean  SE

P

n

LS mean  SE

Pa

2
6
8
12
2
6
8
12
2
6
8
12
2
6
8
12

186
172
164
170
188
170
165
171
184
173
166
174
185
176
167
172

31.4  1.50
18.4  1.54
19.0  1.56
17.5  1.54
31.9  1.50
16.9  1.54
17.4  1.56
16.7  1.54
38.9  1.50
22.7  1.53
23.9  1.55
23.2  1.53
6.1  1.50
5.4  1.53
6.0  1.55
5.6  1.54

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
—
—
—
—

186
172
164
170
188
170
165
171
184
173
166
174
185
176
167
172

40.2  1.72
39.4  1.75
41.9  1.77
40.6  1.76
44.4  1.71
43.6  1.75
43.8  1.76
44.1  1.75
45.6  1.72
45.6  1.75
45.1  1.76
45.6  1.75
7.0  1.72
9.2  1.74
7.9  1.76
6.7  1.75

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
—
—
—
—

186
172
164
170
188
170
165
171
184
173
166
174
186
176
167
174

1.23  0.06
1.32  0.07
1.35  0.07
1.32  0.07
1.37  0.06
1.40  0.07
1.46  0.07
1.42  0.07
1.30  0.07
1.48  0.07
1.45  0.07
1.34  0.07
0.28  0.06
0.30  0.07
0.38  0.07
0.28  0.07

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
—
—
—
—

145
148
140
151
147
150
136
154
140
150
129
159
141
159
143
163

0.99  0.07
1.30  0.07
1.52  0.07
1.52  0.07
1.08  0.07
1.37  0.07
1.64  0.07
1.69  0.07
1.02  0.07
1.48  0.07
1.62  0.08
1.69  0.07
0.76  0.07
1.03  0.07
1.15  0.07
1.28  0.07

0.0260
0.0069
0.0003
0.0149
0.0019
0.0009
<0.0001
<0.0001
0.0105
<0.0001
<0.0001
<0.0001
—
—
—
—

LS, least square; MITT, modified intent-to-treat.
a
TX-004HR versus placebo, based on mixed-effects model repeated measures.
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FIG. 2. Co-primary endpoints: change from baseline to week 12 in (A) percentage of superficial cells; (B) percentage of parabasal cells; (C) vaginal pH
units, and (D) dyspareunia severity scores with three doses of TX-004HR compared with placebo. P < 0.05; yP < 0.0001 versus placebo (MITT
population, n ¼ 747). LS, least square; MITT, modified intent-to-treat.

binding globulin (SHBG) concentrations (measured in a
subset of 72 women) did not increase with treatment relative
to placebo or baseline at week 12. No clinically significant
changes in any laboratory parameters were found.
DISCUSSION
This phase 3 clinical trial demonstrated that TX-004HR at
4, 10, and 25-mg doses is safe and effective for treating
vaginal changes and self-reported symptoms of VVA in
postmenopausal women. Statistically significant and clinically meaningful improvements in all of the four prespecified
co-primary endpoints (increase in the percentage of vaginal
superficial cells, decrease in the percentage of vaginal parabasal cells and vaginal pH, and decrease in severity of the
MBS of dyspareunia) were observed as early as 2 weeks with
all three doses of TX-004HR as compared with placebo, and
were sustained throughout the 12-week trial. Additionally,
statistically significant and potentially clinically meaningful
improvements were found for the secondary endpoints of
vaginal dryness and vulvar and/or vaginal irritation or itching.
These improvements were achieved without increasing
systemic estrogen concentrations (4 and 10 mg) or with
negligible (25 mg) systemic estrogen exposure, as reported
in pharmacokinetic studies.20 TX-004HR was also welltolerated with no clinically significant differences found
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between treatment and placebo groups in any AEs or treatment-related AEs, and no treatment-related serious AEs.
The results reported here extend the findings of a phase 2
study in which TX-004HR demonstrated early onset of action
in the clinical signs of VVA with statistically significantly
improved changes compared with placebo.19 Caution comparing across studies must be utilized; however, when comparing the magnitude of effect with TX-004HR in our study
with those reported for other products with similar study
designs and for a similar indication, the changes with TX004HR were numerically greater. For example, significant
improvements in co-primary endpoints from a randomized
controlled trial of a 10-mg vaginal estradiol tablet were
numerically smaller with the 10-mg estradiol tablet (change
of 13% in superficial cells, 37% in parabasal cells, and 1.3
in vaginal pH)21 than with what was observed in our study
with the 10-mg TX-004HR dose (change of 17% in superficial
cells, 44% in parabasal cells, and 1.4 in vaginal pH) at
12 weeks. In addition, whereas improvements in some objective (cell and pH) endpoints were seen with the estradiol tablet
within 2 weeks of treatment, the participant-reported
improvements in a composite score of subjective symptoms
were not observed until 8 weeks of therapy,21 which may be
perceived as a disadvantage for many users. However, that
clinical trial did not assess individual symptoms.21 A second
ß 2016 The Author(s)
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FIG. 3. Effect of each of three doses of TX-004HR at 12 weeks
compared with placebo on the secondary endpoints of (A) severity of
vaginal dryness and (B) severity of vulvar and/or vaginal itching or
irritation (MITT population, n ¼ 747). P < 0.05; yP < 0.01; zP < 0.0001
versus placebo. LS, least square; MITT, modified intent-to-treat.

separate, randomized controlled trial of 10 and 25-mg estradiol tablets similarly did not find significant improvements
over placebo in the composite score of vaginal symptoms with
either dose until 7 weeks of treatment (wk 2, NS).22 Likewise,
the SERM, ospemifene, was evaluated in another separate
clinical trial for the treatment of dyspareunia, and statistically
significant improvements were not observed until week 12.23
Importantly, the results reported here showed significant
improvement in dyspareunia within 2 weeks with all three
doses of TX-004HR, with reductions in severity scores from
1.5 to 1.7 points at week 12, which were comparable or
superior to reductions of 1.2 to 1.6 points reported for other
currently approved dyspareunia treatments.15,24,25 Additionally, vaginal dryness improved by week 2 with 10 and 25 mg
TX-004HR and by week 6 with 4 mg TX-004HR; such
improvements have been associated with high user satisfaction. Furthermore, TX-004HR 10 and 25 mg showed significant improvement in vaginal irritation and/or itching at week
12, whereas none of the currently available marketed products
reported improvements in these symptoms.26,27

Of note in this study was a large placebo response in the
subjective but not objective measures. This may be explained,
in part, by the potential lubricating properties of the excipient,
Miglyol, found in the placebo vaginal capsules, and also in the
active capsules. Nonetheless, the effect of TX-004HR on
subjective endpoints was superior to the placebo.
Based on a large survey of postmenopausal women in the
United States, only a small proportion (7%) of women are
thought to receive prescription vaginal estrogen therapy alone
for their VVA,4,9 probably due to lack of information about
available treatments, avoidance of discussion of the topic with
healthcare practitioners, or dissatisfaction with currently
available products.4,7,8 Eliminating the need for an applicator
or individually measuring doses is intended to give women a
more positive user experience and thus potentially better
compliance, resulting in overall better efficacy of treatment.
The results with TX-004HR in this study exemplify the
purpose of local vaginal estrogen therapies: rapid symptom
resolution without increasing systemic estrogen concentrations. A pharmacokinetic study of TX-004HR found that
the mean area under the concentration-time curve (AUC) and
average concentration (Cavg) for estradiol were not significantly different from placebo with 4 and 10 mg TX-004HR.20
Although statistically higher AUC for estradiol was observed
with the 25-mg dose, estradiol levels remained within the
postmenopausal range, with no evidence of accumulation by
day 84. Although there was negligible systemic absorption,
rapid efficacy was observed within 2 weeks of dosing with all
doses of TX-004HR.
The low doses of this novel vaginal estradiol soft-gel
capsule, TX-004HR, were well-tolerated.28 Indeed, the four
most commonly reported TEAEs, including vaginal discharge
and vulvovaginal pruritus, were experienced by fewer women
in any TX-004HR group than in the placebo group, and were
mostly mild to moderate in severity. By comparison, in a
12-week study of the efficacy of ospemifene, vaginal
discharge was reported more than six times more frequently
in the ospemifene group than in the placebo group.23 Genital
pruritus was also reported four times more frequently in
women treated with Vagifem 10-mg tablets than with placebo
in a 12-month randomized study.15 Importantly, endometrial
findings after TX-004HR were benign as no hyperplasia or
malignancies were reported in biopsies at 12 weeks.
One of the limitations of this study was the narrowly
defined inclusion criteria. Additionally, women were required
to have identified moderate-to-severe dyspareunia as their
MBS; however, it is well-known that most women with
moderate-to-severe dyspareunia associated with postmenopausal VVA also suffer from multiple other vulvar and
vaginal symptoms. The concept of the MBS has been referred
to as a false construct that may not provide a full clinical
evaluation of a product’s efficacy. Another limitation of this
study is that women were mostly white, in good health, and
had an average BMI of 26.7 kg/m2, and thus, may not be
representative of the US population of postmenopausal
women with VVA.
Menopause, Vol. 24, No. 4, 2017

415

CONSTANTINE ET AL
TABLE 3. Number (%) of TEAEs reported for 3% in any treatment arm of the safety population
TX-004HR 4 mg (n ¼ 191)

Preferred term
Any participant with reported TEAE
Headache
Vaginal discharge
Nasopharyngitis
Vulvovaginal pruritus
Back pain
Urinary tract infection
Upper respiratory tract infection
Oropharyngeal pain

97
12
5
5
4
9
5
5
1

TX-004HR 10 mg (n ¼ 191)

(50.8)
(6.3)
(2.6)
(2.6)
(2.1)
(4.7)
(2.6)
(2.6)
(0.5)

94
14
6
6
3
1
5
6
0

(49.2)
(7.3)
(3.1)
(3.1)
(1.6)
(0.5)
(2.6)
(3.1)
(0)

TX-004HR 25 mg (n ¼ 190)
93
6
4
7
7
4
8
3
6

(48.9)
(3.2)
(2.1)
(3.7)
(3.7)
(2.1)
(4.2)
(1.6)
(3.2)

Placebo (n ¼ 192)
111
15
13
10
10
8
4
5
1

(57.8)
(7.8)
(6.8)
(5.2)
(5.2)
(4.2)
(2.1)
(2.6)
(0.5)

TEAE, treatment-emergent adverse event.

CONCLUSIONS
TX-004HR at doses of 4, 10, and 25 mg was safe and
effective for treating postmenopausal women with VVA
and moderate-to-severe dyspareunia, and also vaginal dryness
and vaginal itching or irritation. Onset of effect was seen as
early as 2 weeks and was maintained throughout the study.
TX-004HR was well-tolerated as reported here and systemic
estrogen exposure was negligible to very low as demonstrated
by the pharmacokinetic study. TX-004HR is a potential novel
product that may provide a promising new treatment option
for women experiencing symptomatic menopausal VVA.
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